BCM
PLRX icon

Bridgeway Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Bridgeway Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$631K Hold
553,630
– – 0.01% 808
2026
Q1 		$698K Buy
553,630
+232,100
+72% +$293K 0.01% 770
2025
Q4 		$392K Buy
321,530
+239,230
+291% +$359K 0.01% 870
2025
Q3 		$122K Hold
82,300
– – ﹤0.01% 1085
2025
Q2 		$95.5K Buy
+82,300
New +$116K ﹤0.01% 1076

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Bridgeway Capital Management's PLRX Position: Q2 2026 in Review

Bridgeway Capital Management held its Pliant Therapeutics (PLRX) position steady in Q2 2026 at 553,630 shares worth $631K. The position accounts for 0.01% of the portfolio, ranked #808.

Bridgeway Capital Management first reported a position in PLRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $698K in Q1 2026. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Bridgeway Capital Management held 553,630 shares of Pliant Therapeutics worth $631K as of Q2 2026.
  • Bridgeway Capital Management left its Pliant Therapeutics share count unchanged in Q2 2026.
  • Pliant Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #808 holding.
  • Bridgeway Capital Management first reported a position in Pliant Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Bridgeway Capital Management's Pliant Therapeutics position peaked at $698K in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.